Use of machine learning to determine deviance in neuroanatomical maturity associated with future psychosis in youths at clinically high risk

• Authors: Yoonho Chung, Yale University; Jean Addington, University of Calgary; Carrie E. Bearden, University of California, Los Angeles; Kristin Cadenhead, University of California, San Diego; Barbara Cornblatt, The Zucker Hillside Hospital; Daniel H. Mathalon, University of California, San Francisco; Thomas McGlashan, Yale University; Diana Perkins, University of North Carolina; Larry J. Seidman, Harvard University; Ming Tsuang, University of California, San Diego; Elaine Walker, Emory University; Scott W. Woods, Yale University; Sarah McEwen, University of California, Los Angeles; Theo G. M. Van Erp, University of California, Irvine; Tyrone D. Cannon, Yale University
• Journal Title: JAMA Psychiatry
• Volume: Volume 75, Number 9
• Publisher: American Medical Association (AMA) | 2018-09-01, Pages 960-968
• Type of Work: Article | Final Publisher PDF
• Publisher DOI: http://doi.org/10.1001/jamapsychiatry.2018.1543
• Subjects: Biology, Neuroscience; Psychology, General

Abstract

Importance: Altered neurodevelopmental trajectories are thought to reflect heterogeneity in the pathophysiologic characteristics of schizophrenia, but whether neural indicators of these trajectories are associated with future psychosis is unclear. Objective: To investigate distinct neuroanatomical markers that can differentiate aberrant neurodevelopmental trajectories among clinically high-risk (CHR) individuals. Design, Setting, and Participants: In this prospective longitudinal multicenter study, a neuroanatomical-based age prediction model was developed using a supervised machine learning technique with T1-weighted magnetic resonance imaging scans of 953 healthy controls 3 to 21 years of age from the Pediatric Imaging, Neurocognition, and Genetics (PING) study and then applied to scans of 275 CHR individuals (including 39 who developed psychosis) and 109 healthy controls 12 to 21 years of age from the North American Prodrome Longitudinal Study 2 (NAPLS 2) for external validation and clinical application. Scans from NAPLS 2 were collected from January 15, 2010, to April 30, 2012. Main Outcomes and Measures: Discrepancy between neuroanatomical-based predicted age (hereafter referred to as brain age) and chronological age. Results: The PING-derived model (460 females and 493 males; age range, 3-21 years) accurately estimated the chronological ages of the 109 healthy controls in the NAPLS 2 (43 females and 66 males; age range, 12-21 years), providing evidence of independent external validation. The 275 CHR individuals in the NAPLS 2 (111 females and 164 males; age range, 12-21 years) showed a significantly greater mean (SD) gap between model-predicted age and chronological age (0.64 [2.16] years) compared with healthy controls (P = .008). This outcome was significantly moderated by chronological age, with brain age systematically overestimating the ages of CHR individuals who developed psychosis at ages 12 to 17 years but not the brain ages of those aged 18 to 21 years. Greater brain age deviation was associated with a higher risk for developing psychosis (F = 3.70; P = .01) and a pattern of stably poor functioning over time, but only among younger CHR adolescents. Previously reported evidence of accelerated reduction in cortical thickness among CHR individuals who developed psychosis was found to apply only to those who were 18 years of age or older. Conclusions and Relevance: These results are consistent with the view that neuroanatomical markers of schizophrenia may help to explain some of the heterogeneity of this disorder, particularly with respect to early vs later age of onset of psychosis, with younger and older individuals having differing intercepts and trajectories in structural brain parameters as a function of age. The results also suggest that baseline neuroanatomical measures are likely to be useful in estimating onset of psychosis, especially (or only) among CHR individuals with an earlier age of onset of prodromal symptoms.